UCIVIDY Trademark
Trademark Overview
On Tuesday, March 28, 2023, a trademark application was filed for UCIVIDY with the United States Patent and Trademark Office. The USPTO has given the UCIVIDY trademark a serial number of 97860535. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Wednesday, December 4, 2024. This trademark is owned by Athira Pharma, Inc.. The UCIVIDY trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceuticals, pharmaceutical preparations and pharmaceutical agents; pharmaceuticals in the nature of small molecule chemical compounds; pharmaceuticals for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical agents for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Scleros...
General Information
| Serial Number | 97860535 |
| Word Mark | UCIVIDY |
| Filing Date | Tuesday, March 28, 2023 |
| Status | 645 - FINAL REFUSAL - MAILED |
| Status Date | Wednesday, December 4, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Pharmaceuticals, pharmaceutical preparations and pharmaceutical agents; pharmaceuticals in the nature of small molecule chemical compounds; pharmaceuticals for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical agents for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, April 4, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Athira Pharma, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Bothell, WA 98011 |
Trademark Events
| Event Date | Event Description |
| Friday, March 31, 2023 | NEW APPLICATION ENTERED |
| Tuesday, April 4, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, December 21, 2023 | ASSIGNED TO EXAMINER |
| Thursday, January 18, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, January 18, 2024 | NON-FINAL ACTION E-MAILED |
| Thursday, January 18, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, January 26, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Friday, January 26, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Monday, July 15, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, July 16, 2024 | ASSIGNED TO EXAMINER |
| Friday, October 25, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, December 4, 2024 | FINAL REFUSAL WRITTEN |
| Wednesday, December 4, 2024 | FINAL REFUSAL E-MAILED |
| Wednesday, December 4, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Monday, July 15, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, July 15, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
